P1.01-134 SAVANNAH: Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib

Autor:	Ghada F. Ahmed, Mireille Cantarini, Paul Frewer, Ryan J. Hartmaier, Jane Peters, Geoffrey R. Oxnard, M-J. Ahn, G. Hawkins, Tarjinder Sahota, Xiaocheng Li-Sucholeiki, P. Howarth
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine Oncology Savolitinib business.industry Mutant Cancer research Medicine Osimertinib business
Zdroj:	Journal of Thoracic Oncology. 14:S415-S416
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2019.08.849
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0d571b91f7f2fe5dd35761a12d946688 https://doi.org/10.1016/j.jtho.2019.08.849 Zobrazit plný text záznamu